<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19322">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855346</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-030/IPM 041</org_study_id>
    <secondary_id>5UM1 A1068633</secondary_id>
    <nct_id>NCT02855346</nct_id>
  </id_info>
  <brief_title>PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel</brief_title>
  <acronym>DAP/LNG</acronym>
  <official_title>A Phase 1, Randomized, Double-Blind Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PK and Safety Study of Vaginal Ring Containing Dapivirine and Levonorgestrel
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Randomized, Double-Blind Pharmacokinetic and Safety Study of
      Dapivirine/Levonorgestrel
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dapivirine and levonorgestrel concentrations in blood and Vaginal fluid</measure>
    <time_frame>14 days</time_frame>
    <description>To characterize the local and systemic pharmacokinetics of one dapivirine vaginal ring formulation and two dapivirine-levonorgestrel vaginal ring formulations used continuously for 14 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 2 or higher Genitourinary adverse event and Grade 3 or higher adverse event as defined by DAIDS</measure>
    <time_frame>14 days</time_frame>
    <description>To evaluate the safety of one dapivirine vaginal ring formulation and two dapivirine-levonorgestrel vaginal ring formulations used continuously for 14 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>200 mg of DPV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg of DPV + 320 mg LNG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ring 104</intervention_name>
    <description>DPV VR, containing 200 mg DPV</description>
    <arm_group_label>200 mg of DPV</arm_group_label>
    <other_name>Dapivirine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ring 102</intervention_name>
    <description>DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG</description>
    <arm_group_label>200 mg of DPV + 320 mg LNG</arm_group_label>
    <other_name>Dapivirine/Levonorgestrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women

        Exclusion Criteria:

          -  HIV infected women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sharon Achilles, MD, PHD,</last_name>
    <phone>1+(412)641-1403</phone>
    <email>achisx@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatrice A Chen, MPH</last_name>
    <phone>1+(412)6411403</phone>
    <email>chenba@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Magee Women's Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig Hoesley, MD</last_name>
      <phone>205-934-3365</phone>
      <email>choesley@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Beatrice Chen, MD, MPH</last_name>
      <phone>412-641-1403</phone>
      <email>chenba@upmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>June 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
